Observational study on immune thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study follows people who have immune thrombocytopenia (ITP), a condition where the blood doesn't clot properly because of low platelets. By tracking patients over time, researchers hope to learn more about the disease and how it affects people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of immune thrombocytopenia (ITP).
- You must have received treatment for ITP at Peking University People's Hospital since January 1, 2005.
- You should not have a severe psychiatric condition that could interfere with reliable follow-up.
- You must be willing to attend follow-up visits as required by the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients who have both immune thrombocytopenia (ITP) and a recent ischemic stroke to learn more about their health over time. If you fit these criteria, joining may help doctors better understand how to care for people with these conditions.
This study looks at how people with immune thrombocytopenia (ITP) are treated in real life. It aims to understand which treatments work best for patients who have had ITP for up to 12 months.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
This study tests a new combination of two medicines—one that calms the immune system and one that helps your body make more platelets. It is for people with long-term ITP who have already tried other treatments and still have low platelet counts.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.